Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: A pilot study

Breast Cancer

Volumn 18, Issue 4, 2011, Pages 299-308

  Ueda, Shigeto ^a,c,e   Tsuda, Hitoshi ^a   Saeki, Toshiaki ^b,c   Omata, Jiro ^a   Osaki, Akihiko ^b,c   Shigekawa, Takashi ^b,c   Ishida, Jiro ^d   Tamura, Katsumi ^d   Abe, Yoshiyuki ^d   Moriya, Tomoyuki ^a   Yamamoto, Junji ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Tokorozawa Ichou Hospital   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d Tokorozawa PET Diagnostic Imaging Clinic   (Japan)

^e Ministry of Defense   (Japan)

Author keywords

Breast cancer; FDG PET CT; Neoadjuvant endocrine therapy; SUV

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR;

AGED; ANALYTICAL PARAMETERS; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SIZE; CANCER TISSUE; CELL CYCLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EARLY METABOLIC RESPONSE; ECHOGRAPHY; FEASIBILITY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MUCINOUS CARCINOMA; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; POSTMENOPAUSE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIAZOLES;

EID: 82155203038     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-010-0212-y     Document Type: Article

References (31)

1. M Kaufmann G von Minckwitz HD Bear A Buzdar P McGale H Bonnefoi, et al. 2007 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann Oncol 18 12 1927 1934 17998286 10.1093/annonc/mdm201 1:STN:280:DC%2BD2sjkt1KlsA%3D%3D (Pubitemid 350286227)
2. EJ Macaskill L Renshaw JM Dixon 2006 Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer Oncologist 11 10 1081 1088 17110627 10.1634/theoncologist.11-10- 1081 1:CAS:528:DC%2BD28XhtlCrs7nE (Pubitemid 44788399)
3. MJ Ellis C Ma 2007 Letrozole in the neoadjuvant setting: the P024 trial Breast Cancer Res Treat 105 Suppl 1 33 43 17912634 10.1007/s10549-007-9701-x 1:CAS:528:DC%2BD2sXhtlektrbF (Pubitemid 47524802)
4. IE Smith M Dowsett SR Ebbs JM Dixon A Skene JU Blohmer, et al. 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 22 5108 5116 15998903 10.1200/JCO.2005.04.005 1:CAS:528:DC%2BD2MXpsFWmtLY%3D (Pubitemid 46224019)
5. H Takei K Suemasu K Inoue T Saito K Okubo J Koh, et al. 2008 Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03) Breast Cancer Res Treat 107 1 87 94 18043897 10.1007/s10549-007-9529-4 1:CAS:528:DC%2BD2sXhtlGrtbvN (Pubitemid 350179589)
6. MJ Ellis 2005 Neoadjuvant endocrine therapy for breast cancer: more questions than answers J Clin Oncol 23 22 4842 4844 15998901 10.1200/JCO.2005.92.003 1:CAS:528:DC%2BD2MXpsFWmt74%3D (Pubitemid 46237439)
7. M Dowsett IE Smith SR Ebbs JM Dixon A Skene C Griffith, et al. 2006 Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer Clin Cancer Res 12 3 Pt 2 1024s 1030s 16467120 10.1158/1078-0432.CCR-05-2127 1:CAS:528:DC%2BD28XhtFeitL0%3D (Pubitemid 43259839)
8. M Dowsett IE Smith SR Ebbs JM Dixon A Skene R A'Hern, et al. 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 2 167 170 17228000 10.1093/jnci/djk020 1:CAS:528:DC%2BD2sXhvVOhtbc%3D
9. MJ Ellis Y Tao J Luo R A'Hern DB Evans AS Bhatnagar, et al. 2008 Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 19 1380 1388 18812550 10.1093/jnci/djn309 1:CAS:528:DC%2BD1cXht1Sitb7F
10. F Dehdashti JE Mortimer K Trinkaus MJ Naughton M Ellis JA Katzenellenbogen, et al. 2009 PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor- positive breast cancer Breast Cancer Res Treat 113 3 509 517 18327670 10.1007/s10549-008-9953-0 1:CAS:528:DC%2BD1MXotValsw%3D%3D
11. ME Juweid BD Cheson 2006 Positron-emission tomography and assessment of cancer therapy N Engl J Med 354 5 496 507 16452561 10.1056/NEJMra050276 1:CAS:528:DC%2BD28Xptlajsw%3D%3D (Pubitemid 43200300)
12. WA Weber SI Ziegler R Thodtmann AR Hanauske M Schwaiger 1999 Reproducibility of metabolic measurements in malignant tumors using FDG PET J Nucl Med 40 11 1771 1777 10565769 1:STN:280:DC%2BD3c%2FivFCquw%3D%3D (Pubitemid 29523568)
13. S Ueda H Tsuda H Asakawa T Shigekawa K Fukatsu N Kondo, et al. 2008 Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer Jpn J Clin Oncol 38 4 250 258 18407934 10.1093/jjco/hyn019 (Pubitemid 351583988)
14. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma, et al. 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 13 1773 1782 10673991 10.1016/S0959-8049(99)00229-4 1:STN:280:DC%2BD3c7jvV2ntA%3D%3D (Pubitemid 29512308)
15. LK Shankar JM Hoffman S Bacharach MM Graham J Karp AA Lammertsma, et al. 2006 Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 6 1059 1066 16741317 1:CAS:528:DC%2BD28XmtlWmt7s%3D (Pubitemid 46939960)
16. GL Cascini A Avallone P Delrio C Guida F Tatangelo P Marone, et al. 2006 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer J Nucl Med 47 8 1241 1248 16883000 1:CAS:528:DC%2BD28XptVWqu74%3D (Pubitemid 47544874)
17. C Rousseau A Devillers C Sagan L Ferrer B Bridji L Campion, et al. 2006 Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography J Clin Oncol 24 34 5366 5372 17088570 10.1200/JCO.2006.05.7406 (Pubitemid 46623167)
18. J Dose Schwarz M Bader L Jenicke G Hemminger F Janicke N Avril 2005 Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med 46 7 1144 1150 16000283 (Pubitemid 43741076)
19. S Ueda N Kondoh H Tsuda S Yamamoto H Asakawa K Fukatsu, et al. 2008 Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer BMC Cancer 8 384 19102762 10.1186/1471-2407-8-384
20. M Kurosumi S Akashi-Tanaka F Akiyama Y Komoike H Mukai S Nakamura, et al. 2008 Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version) Breast Cancer 15 1 5 7 18224386 10.1007/s12282-007-0016-x
21. H Tsuda Y Tani T Hasegawa T Fukutomi 2001 Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma Pathol Int 51 1 26 32 11148460 10.1046/j.1440-1827.2001.01163.x 1:CAS:528:DC%2BD3MXhvFKntLo%3D (Pubitemid 32158808)
22. H Tsuda D Morita M Kimura E Shinto Y Ohtsuka O Matsubara, et al. 2005 Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation Cancer Sci 96 1 48 53 15649255 10.1111/j.1349-7006.2005.00009.x 1:CAS:528:DC%2BD2MXhtlamsLs%3D (Pubitemid 40310025)
23. S Ueda H Tsuda K Sato H Takeuchi T Shigekawa O Matsubara, et al. 2006 Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1 Cancer Sci 97 7 597 604 16827799 10.1111/j.1349-7006.2006.00228. x 1:CAS:528:DC%2BD28XmsVOnt7c%3D (Pubitemid 44056607)
24. DC Allred JM Harvey M Berardo GM Clark 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 2 155 168 9504686 1:STN:280:DyaK1c7mtlaitg%3D%3D (Pubitemid 28144151)
25. UE Krainick-Strobel W Lichtenegger D Wallwiener AH Tulusan F Janicke G Bastert, et al. 2008 Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy BMC Cancer 8 62 18302747 10.1186/1471-2407-8-62 (Pubitemid 351454862)
26. M Schelling N Avril J Nahrig W Kuhn W Romer D Sattler, et al. 2000 Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 8 1689 1695 10764429 1:STN:280:DC%2BD3c3islyjsw%3D%3D (Pubitemid 30220547)
27. J Duch D Fuster M Munoz PL Fernandez P Paredes M Fontanillas, et al. 2009 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer Eur J Nucl Med Mol Imaging 36 1551 1557 19326117 10.1007/s00259-009-1116-y 1:CAS:528:DC%2BD1MXht1WhtL3L
28. F Pons J Duch D Fuster 2009 Breast cancer therapy: the role of PET-CT in decision making Q J Nucl Med Mol Imaging 53 2 210 228 19293769 1:STN:280:DC%2BD1M3hs1Whuw%3D%3D
29. M Kurosumi Y Takatsuka T Watanabe S Imoto H Inaji H Tsuda, et al. 2008 Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial J Cancer Res Clin Oncol 134 6 715 722 18075758 10.1007/s00432-007-0343-5 1:CAS:528:DC%2BD1cXksVKrurc%3D
30. Y Tao A Klause A Vickers K Bae M Ellis 2005 Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials J Steroid Biochem Mol Biol 95 1-5 91 95 15994076 10.1016/j.jsbmb.2005.04.017 1:CAS:528: DC%2BD2MXntVOhurY%3D (Pubitemid 41137298)
31. MJ Ellis Y Tao O Young S White AD Proia J Murray, et al. 2006 Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole J Clin Oncol 24 19 3019 3025 16754938 10.1200/JCO.2005.04.3034 1:CAS:528:DC%2BD28XnslKhsrY%3D (Pubitemid 46638935)